BioAtla (BCAB) News Today → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free BCAB Stock Alerts $2.88 -0.25 (-7.99%) (As of 01:45 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBioAtla (BCAB) to Release Earnings on Tuesdaymarketbeat.com - May 8 at 10:17 AMBioAtla to Participate in the Citizens JMP Life Sciences Conferenceglobenewswire.com - May 8 at 8:00 AMBioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024finance.yahoo.com - May 7 at 7:57 PMBioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of Multiple Tumorsmarkets.businessinsider.com - May 6 at 10:04 AMBioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumorsglobenewswire.com - May 6 at 8:00 AMBioAtla, Inc. Common Stock (BCAB)nasdaq.com - May 3 at 8:45 PMBioAtla: A Buried ADC Concern Gets Some New Life In 2024seekingalpha.com - May 2 at 2:32 PMBioAtla, Inc. (BCAB)finance.yahoo.com - April 30 at 3:30 PMBioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.com - April 24 at 4:35 PMBuy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stabilitymarkets.businessinsider.com - April 11 at 2:38 AMGRIN, WOOF and MRNS are among after hour moversseekingalpha.com - April 5 at 11:05 PMBioAtla, Inc. Expected to Earn FY2028 Earnings of ($0.09) Per Share (NASDAQ:BCAB)marketbeat.com - March 29 at 9:25 AMBioAtla's (BCAB) "Market Outperform" Rating Reiterated at JMP Securitiesmarketbeat.com - March 28 at 11:29 AMOptimistic Outlook for BioAtla’s Pipeline Progression and Potential Partnershipsmarkets.businessinsider.com - March 27 at 1:30 PMBioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 1:30 PMBioAtla: Q4 Earnings Insightsbenzinga.com - March 26 at 10:57 PMBioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Resultsfinance.yahoo.com - March 26 at 10:57 PMBioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progressglobenewswire.com - March 26 at 4:01 PMPreview: BioAtla's Earningsbenzinga.com - March 25 at 4:20 PMBioAtla (BCAB) Set to Announce Earnings on Tuesdaymarketbeat.com - March 20 at 3:04 PMBioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024globenewswire.com - March 19 at 8:00 AMBioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - March 7 at 8:00 AMDeutsche Bank AG Sells 413,268 Shares of BioAtla, Inc. (NASDAQ:BCAB)marketbeat.com - March 7 at 4:21 AMBioAtla, Inc.edition.cnn.com - March 6 at 6:58 PMMassachusetts Financial Services Co. MA Sells 227,686 Shares of BioAtla, Inc. (NASDAQ:BCAB)marketbeat.com - February 13 at 5:19 AMStrong Buy for BioAtla: Promising ADC Developments and Strategic Oncology Pipelinemarkets.businessinsider.com - January 24 at 7:52 AMBuy Rating for BioAtla Amid Robust Pipeline and Encouraging Clinical Trialsmarkets.businessinsider.com - January 10 at 1:44 PMBTIG Keeps Their Buy Rating on BioAtla (BCAB)markets.businessinsider.com - January 1 at 12:09 AMCo-Founder of BioAtla Jay Short Buys 2.3% More Sharesfinance.yahoo.com - December 23 at 10:34 AMBioAtla CEO purchases 50K common sharesmsn.com - December 21 at 2:08 PMBioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - December 20 at 8:34 AMStrong Buy Rating for BioAtla Reflects Potential of BA3071 and Promising Clinical Resultsmarkets.businessinsider.com - December 18 at 10:50 PMBioAtla, Inc. (NASDAQ:BCAB) Short Interest Updatemarketbeat.com - December 16 at 11:59 AMAfter losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gainfinance.yahoo.com - December 15 at 10:04 AMBuy Rating Affirmed for BioAtla Amid Promising BA3071 Clinical Data and Favorable Safety Profilemarkets.businessinsider.com - December 14 at 11:32 PMBioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Typesfinance.yahoo.com - December 13 at 8:17 AMBioAtla Inc Ordinary Sharesmorningstar.com - December 12 at 10:28 AMBioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023finance.yahoo.com - December 6 at 9:26 AMStrong Buy Rating for BioAtla Amid BA3011’s Promising Efficacy and Strategic FDA Engagementmarkets.businessinsider.com - December 5 at 11:28 PMBioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Eventfinance.yahoo.com - December 5 at 8:27 AMBCAB, DUNE and CDT among mid-day moversmsn.com - December 4 at 2:08 PMBioAtla to Participate in the JMP Securities Hematology and Oncology Summitfinance.yahoo.com - November 30 at 10:25 AMBioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLCfinance.yahoo.com - November 28 at 10:59 AMBioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 12 at 1:24 PMAnalysts Offer Insights on Healthcare Companies: BioAtla (BCAB) and Silk Road Medical (SILK)markets.businessinsider.com - November 9 at 3:09 PMBioAtla Inc Ordinary Shares BCABmorningstar.com - November 8 at 1:12 AMBioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progressfinance.yahoo.com - November 7 at 8:11 PMWe're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Ratefinance.yahoo.com - October 20 at 9:42 AMPromising Outlook for BioAtla’s ADCs in NSCLC Treatment Bolsters Buy Ratingmarkets.businessinsider.com - October 17 at 9:00 AMBioAtla Inc Registered Shs hosts conference call for investorsmarkets.businessinsider.com - October 13 at 1:41 AM Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Proof that the Musk/Bezos rivalry is about to hit a new level (Ad)Elon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats… Go here now for full story. BCAB Media Mentions By Week BCAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAB News Sentiment▼0.230.36▲Average Medical News Sentiment BCAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAB Articles This Week▼71▲BCAB Articles Average Week Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRDF News SCLX News CRDL News MOLN News VXRT News DBVT News CLLS News GNFT News VIGL News OMGA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAB) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
